Abstract:To give full prominence to the superiority of phenolic acid nutraceuticals syringic acid (SYRA) and gallic acid (GALA) in perfection of in vitro and in vivo performances for cardiotonic drug milrinone (MLN), and ulteriorly attain novice insights in the development of cardiotonic drug-nutraceutical cocrystals, two new solid forms of MLN including one cocrystal with SYRA, and one cocrystal hydrate with GALA─namely, MLN-SYRA (1) and MLN-GALA- H2O (2)─are first assembled and thoroughly characterized. The single-crystal X-ray diffraction showcases that both cocrystal 1 and cocrystal hydrate 2 have three-dimensional supramolecular structures controlled by hydrogen-bonding and aromatic packing interactions, where the hydrogen-bonding dimers of MLN itself still remain in 1 but are broken in 2, forming hydrophobic cavities in the former and hydrophilic ones in the latter. Such structural characteristics and aggregation motifs, because of the introduction of different phenolic acids in the crystalline lattices, have important influence on the improvements of dissolvability and permeability for the two crystalline forms, and in accordance with the theoretical studies. Intriguingly, the optimized in vitro biopharmaceutical properties can be effectually transformed to satisfactory in vivo pharmacokinetic peculiarity, performing the increased bioavailability and extended half-life. Thus, the current research not only offers promising solid-state forms for MLN with development foregrounds, but opens up new applications for nutraceutical phenolic acids in cardiotonic pharmaceutical cocrystals.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.cgd.1c01143.Screenings for the cocrystal of MLN with phenolic acids; screenings for the MLN-SYRA cocrystal with different methods; screenings for the MLN-GALA-H2O cocrystal hydrate with different experimental parameters; some parameters related to molecular electrostatic potentials, DSC and TG profiles of starting materials, powder XRD comparison of simulated pattern for the cocrystals and the residual solids after the solubility tests, IDR profiles of MLN, cocrystal 1 and cocrystal hydrate 2 at pH 1.2, 4.0, and 6.8 buffers (PDF)This article has not yet been cited by other publications.

Pharmaceutical Cocrystals of Nicorandil with Enhanced Chemical Stability and Sustained Release

Enhanced solubility, permeability, and tabletability of nicorandil by salt and cocrystal formation

Pharmaceutical Cocrystals: A Novel Systematic Approach for the Administration of Existing Drugs in New Crystalline Form

Preparation and Characterization of Novel Pharmaceutical Co-Crystals: Ticagrelor with Nicotinamide

Novel Polymorphic Cocrystals of the Non-Steroidal Anti-Inflammatory Drug Niflumic Acid: Expanding the Pharmaceutical Landscape

Insight into the Structure and Property Diversity of Four Nicorandil Oxalate Salt Polymorphs Based on Experiments and Quantum Chemistry Study

Novel Pharmaceutical Cocrystal of Lenalidomide with Nicotinamide: Structural Design, Evaluation, and Thermal Phase Transition Study.

Assessing Structures and Solution Behaviors of Molecular and Ionic Cocrystals with a Common Bioactive Molecule: 2,4-Pyridinedicarboxylic Acid with Tranexamic Acid and Nicotinamide

Phenazopyridine-phthalimide Nano-Cocrystal: Release Rate and Oral Bioavailability Enhancement.

Mechanistic Study on Transformation of Coamorphous Baicalein-Nicotinamide to Its Cocrystal Form

Chemical stabilization strategy for cymoxanil: synthesis and characterization of cocrystals with small organic acids

Novel Aceclofenac-l-Cystine and Aceclofenac-Urea Cocrystals with Enhanced Oral Bioavailability.

Exploring the formation and diversity of secnidazole cocrystals

The Binary System of Ibuprofen-Nicotinamide Under Nanoscale Confinement: From Cocrystal to Coamorphous State

Synthesis, Performance, and Thermal Behavior of Two Insensitive 3,4-Dinitropyrazole-Based Energetic Cocrystals

The First Cocrystallization of Milrinone with Nutraceuticals: The Adjusting Effects of Hydrophilicity/Hydrophobicity in Cavities on the In Vitro/In Vivo Properties of the Cocrystals

A novel drug-drug coamorphous system without molecular interactions: improve the physicochemical properties of tadalafil and repaglinide

Solution Stability of Pharmaceutical Cocrystals

Melt Crystallization of Celecoxib-Carbamazepine Cocrystals with the Synchronized Release of Drugs

Celecoxib:nicotinamide dissociation: using excipients to capture the cocrystal's potential

Bioavailability-Enhancing Cocrystals: Screening, In Vivo Predictive Dissolution, and Supersaturation Maintenance